With a market capitalization (market cap) of $1.79B — a measure of how much the company is worth — Zenas BioPharma, Inc. ranks #2,124 among the 2,510 companies tracked, and 272nd in Healthcare as of October 3, 2026. Shares trade at $28.30, up 1.27% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.79B | -11.58% | $28.30 |
| 2025 | Dec 31, 2025 | $2.02B | +489.96% | $36.31 |
| 2024 | Dec 31, 2024 | $342.35M | — | $8.19 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.79B as of October 3, 2026.
Zenas BioPharma, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $28.30 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.79B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 44,730,052 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.27B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Zenas BioPharma, Inc. (ZBIO) is worth $1.79B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Zenas BioPharma, Inc.’s book equity is about $242.14M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $1.79B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Zenas BioPharma, Inc. ranks #2,124 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #272 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2121 | Youdao, Inc. DAO | $1.79B | 0.00% |
| #2122 | SFL Corporation Ltd SFL | $1.79B | -0.22% |
| #2123 | Sonida Senior Living, Inc. SNDA | $1.79B | -0.19% |
| #2125 | Azenta, Inc. AZTA | $1.79B | +12.38% |
| #2126 | Vermilion Energy Inc. VET | $1.78B | +0.69% |
| #2127 | Nuvation Bio Inc. NUVB | $1.78B | -7.55% |
Zenas BioPharma, Inc.’s ranking market cap of $1.79B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 44,730,052. The historical market-cap series last observed $1.79B on October 2, 2026.
Over the past year, Zenas BioPharma, Inc.’s market cap is up 83.33%, using historical market-cap records rather than today’s share count applied to past prices.
Zenas BioPharma, Inc. (ZBIO) shares trade at $28.30, up 1.27% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.